Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus

NCT03472014 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT03472014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03472014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus
Lead sponsor
Bavarian Nordic
Phase
Phase 4
Overall status
Completed
Start date
April 22, 2010
Completion date
November 14, 2014
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vaccination